A Case of Disseminated Intra-abdominal Gastrointestinal Stromal Tumor Managed with Low Dose Imatinib | Zendy

Bo Hyun Jang | Zendy; ByungWook Kim | Zendy; Keun Joon Lim | Zendy; Boo Gyoung Kim | Zendy; Sung-Min Park | Zendy; Joon Sung Kim | Zendy; JeongSeon Ji | Zendy; Hwang Choi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Case of Disseminated Intra-abdominal Gastrointestinal Stromal Tumor Managed with Low Dose Imatinib

Author(s) -

Bo Hyun Jang,

ByungWook Kim,

Keun Joon Lim,

Boo Gyoung Kim,

Sung-Min Park,

Joon Sung Kim,

JeongSeon Ji,

Hwang Choi

Publication year - 2015

Publication title -

korean journal of gastroenterology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.203

H-Index - 25

eISSN - 2233-6869

pISSN - 1598-9992

DOI - 10.4166/kjg.2015.65.6.366

Subject(s) - gist , medicine , imatinib mesylate , stromal tumor , imatinib , adverse effect , gastrointestinal tract , adjuvant therapy , oncology , gastroenterology , surgery , stromal cell , chemotherapy , myeloid leukemia

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. Imatinib mesylate is recommended as adjuvant therapy for GIST after surgical resection. However, drug-related adverse events are common. A 74-year-old female with metastatic GIST who was managed with imatinib experienced severe adverse events, including skin rashes, tremor, and alopecia, etc. The imatinib dose was reduced and the size of the metastatic GIST continued to decrease and adverse events showed significant improvement.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research